Jeb Bush Fires Back at Trump, but Is Anyone Listening?
Despite the sizzling Summer of Trump, Jeb Bush and the rest of the Republican establishment still don’t get it.
Bush just released an 80-second video entitled “The Real Donald Trump”, as flagged by Mike Allen in his Politico Playbook note this morning, in a slick effort to attack Trump by using his own words against him. That’s a classic campaign tactic, of course, and the effort by the Bush campaign is aimed at painting the bombastic real estate mogul from New York as a fake conservative – someone whose core values and views are anathema to Republicans in Iowa, where the Real Clear Politics poll average puts Trump in the lead for the GOP Caucuses with 21.3 percent.
Related: Two New Polls Show Exactly Why Donald Trump Is Winning
Here’s a sampling from the video:
Talking to Tim Russert on Meet the Press, 1999:
- “I’ve lived in New York City and Manhattan all my life, so you know my views are a little bit different than if I lived in Iowa.”
- “I am very pro-choice. I am pro-choice in every respect.”
From a 1999 Fox News clip:
- “As far as single-payer [heathcare system], it works in Canada. It works incredibly well in Scotland.”
Talking to Wolf Blitzer on CNN:
- Who would you like representing the United States in a deal with Iran? “I think Hillary would do a good job.”
- Do you identify more as a Democrat or a Republican? “Well, you’d be shocked if I said that in many cases I probably identify more as a Democrat.”
From a 2001 Fox News clip:
- “Hillary Clinton is a terrific woman. I’m a little biased because I’ve known her for years.”
Some of the clips are 15 years old or older and show Trump for what he was: a New Yorker with unremarkable New York liberal/centrist positions on a lot of issues.
Related: Fiorina PAC: CNN and GOP Are Conspiring Against Carly
The big question for Bush and other Republican politicians in the race is: Does it matter that much where Trump once stood or even where he now stands? If it doesn’t, that is going to make taking him down even more difficult.
What Trump is selling is unvarnished authenticity to an electorate tired of politicians who try to be all things to all people. You’re not going to catch Trump courting the gun crowd by saying he likes to hunt small varmints, like the patrician Mitt Romney did. Or donning a Rocky the Squirrel hat and riding around in a tank like Mike Dukakis did in 1988 to try to show he could be a credible commander-in-chief.
Mad-as-hell voters are sick of phoniness and goofy photo ops. When will the career politicians get that?
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.